)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Aurinia Pharmaceuticals (AUPH) investor relations material
Aurinia Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary4 Nov, 2025
Executive summary
LUPKYNIS sales grew 27% year-over-year in Q3 2025, driven by strong demand, updated treatment guidelines, and increased prescriber adoption.
Net product sales for the nine months ended September 30, 2025, increased 24% year-over-year, with total revenue up 17% to $205.9M.
Net income surged 119% in Q3 and 1,677% for the nine months, with diluted EPS up 130% in Q3 and 1,733% for the nine months.
Aritinercept, a dual BAFF/APRIL inhibitor, advanced toward clinical studies in two autoimmune diseases, with positive Phase 1 results and further details expected in early 2026.
Strategic restructuring in 2024 reduced headcount by approximately 70% and discontinued the AUR300 program, focusing resources on LUPKYNIS and aritinercept.
Financial highlights
Q3 2025 total revenue: $73.5M, up 8% from Q3 2024; nine months: $205.9M, up 17% year-over-year.
LUPKYNIS net product sales: $70.6M in Q3 (up 27% YoY); $197.2M for nine months (up 24% YoY).
Q3 2025 net income: $31.6M, up 119% YoY; nine months: $76.4M, up 1,677% YoY.
Cash flows from operating activities: $44.5M in Q3 (up 162%), $90M for nine months (up 529%).
Cash, equivalents, and investments: $351.8M as of September 30, 2025.
Outlook and guidance
2025 total revenue guidance raised to $275M–$280M; net product sales guidance raised to $265M–$270M.
LUPKYNIS expected to maintain positive momentum into Q4 and 2026, supported by updated treatment guidelines.
Clinical studies for aritinercept in two autoimmune diseases planned by year-end 2025, with more details in early 2026.
SG&A expenses expected to remain lower in 2025 due to restructuring, while R&D expenses are projected to increase.
The company expects to fund future operations with existing cash or future operating cash flows.
What drives LUPKYNIS sales momentum?
Aritinercept target diseases and study timeline?
Future capital allocation strategy
LUPKYNIS market share evolution vs. Gazyva
Aritinercept indication selection criteria
Key drivers of LUPKYNIS patient persistence
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aurinia Pharmaceuticals earnings date
Q4 202526 Feb, 2026
Next Aurinia Pharmaceuticals earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aurinia is a biopharmaceutical company driven by a relentless commitment to bring life-changing therapies, like voclosporin, to patients suffering from diseases with high unmet medical need. The Company’s lead product, voclosporin, is being investigated as a therapy for LN. The Company is initially targeting LN and has plans to study additional disease indications. The company is headquartered in Victoria, Canada.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage